Abacavir/lamivudine + unboosted atazanavir in routine clinical practice: Twelve years experience.

[1]  R. Crutchley,et al.  Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection , 2016, HIV/AIDS.

[2]  D. Wohl,et al.  The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir† , 2015, HIV medicine.

[3]  A. Geretti,et al.  HIV: new drugs, new guidelines , 2014, Current opinion in infectious diseases.

[4]  S. Mercadante,et al.  Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. , 2014, Current HIV research.

[5]  D. Wohl,et al.  Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial , 2014, PloS one.

[6]  A. Mocroft,et al.  Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression , 2014, Journal of the International AIDS Society.

[7]  D. Ward,et al.  ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine , 2012, HIV clinical trials.

[8]  T. Poulos,et al.  Interaction of human cytochrome P4503A4 with ritonavir analogs. , 2012, Archives of biochemistry and biophysics.

[9]  A. Lazzarin,et al.  Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen , 2010, Antiviral therapy.

[10]  K. Squires,et al.  Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients , 2010, AIDS.

[11]  Yujin Wang,et al.  Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. , 2010, ACS medicinal chemistry letters.

[12]  V. Soriano,et al.  Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. , 2008, AIDS research and human retroviruses.